CN111868083B - 因子h增强抗体及其用途 - Google Patents

因子h增强抗体及其用途 Download PDF

Info

Publication number
CN111868083B
CN111868083B CN201980019128.3A CN201980019128A CN111868083B CN 111868083 B CN111868083 B CN 111868083B CN 201980019128 A CN201980019128 A CN 201980019128A CN 111868083 B CN111868083 B CN 111868083B
Authority
CN
China
Prior art keywords
sequence
seq
antibody
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980019128.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111868083A (zh
Inventor
塔卡·威廉·库依普斯
黛安娜·武泰
玛利亚·克莱尔·布劳威尔
理查德·本杰明·普维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanquin
Original Assignee
Sanquin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin filed Critical Sanquin
Publication of CN111868083A publication Critical patent/CN111868083A/zh
Application granted granted Critical
Publication of CN111868083B publication Critical patent/CN111868083B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980019128.3A 2018-01-15 2019-01-15 因子h增强抗体及其用途 Active CN111868083B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18151726.9 2018-01-15
EP18151726 2018-01-15
PCT/NL2019/050018 WO2019139481A1 (en) 2018-01-15 2019-01-15 Factor h potentiating antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN111868083A CN111868083A (zh) 2020-10-30
CN111868083B true CN111868083B (zh) 2025-02-11

Family

ID=60972152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980019128.3A Active CN111868083B (zh) 2018-01-15 2019-01-15 因子h增强抗体及其用途

Country Status (11)

Country Link
US (2) US11377487B2 (cg-RX-API-DMAC7.html)
EP (1) EP3740502A1 (cg-RX-API-DMAC7.html)
JP (2) JP7471224B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250171487A (cg-RX-API-DMAC7.html)
CN (1) CN111868083B (cg-RX-API-DMAC7.html)
AU (1) AU2019206207B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014399A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088507A1 (cg-RX-API-DMAC7.html)
IL (1) IL276008A (cg-RX-API-DMAC7.html)
MX (1) MX2020007555A (cg-RX-API-DMAC7.html)
WO (1) WO2019139481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019206207B2 (en) * 2018-01-15 2025-04-10 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
JP7631296B2 (ja) * 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド H因子増強性抗体及びその使用
KR20230113578A (ko) * 2020-11-27 2023-07-31 선샤인 레이크 파르마 컴퍼니 리미티드 Cldn18.2 항체 및 그의 용도
KR20240040098A (ko) * 2021-07-30 2024-03-27 알.피.쉐러 테크놀러지즈 엘엘씨 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법
CN116355860A (zh) * 2021-12-28 2023-06-30 四川远大蜀阳药业有限责任公司 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用
CN116655792B (zh) * 2022-03-21 2024-01-02 南京蓬勃生物科技有限公司 靶向Siglec-15的单克隆抗体及其应用
NL2032398B1 (en) * 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
CN118878671B (zh) * 2024-07-04 2025-09-30 南京农业大学 抗兽疫链球菌SzM蛋白的猪源化单克隆抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028150A1 (en) * 2014-08-20 2016-02-25 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
KR102485788B1 (ko) 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
AU2019206207B2 (en) * 2018-01-15 2025-04-10 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
JP7631296B2 (ja) * 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド H因子増強性抗体及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028150A1 (en) * 2014-08-20 2016-02-25 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
CN107074939A (zh) * 2014-08-20 2017-08-18 桑昆血液供给基金会 H因子增强抗体及其用途

Also Published As

Publication number Publication date
CN111868083A (zh) 2020-10-30
JP2021510523A (ja) 2021-04-30
KR20250171487A (ko) 2025-12-08
AU2019206207A1 (en) 2020-08-13
AU2019206207B2 (en) 2025-04-10
BR112020014399A2 (pt) 2020-12-29
KR102896085B1 (ko) 2025-12-08
US20210054059A1 (en) 2021-02-25
WO2019139481A1 (en) 2019-07-18
US11377487B2 (en) 2022-07-05
EP3740502A1 (en) 2020-11-25
JP2023089191A (ja) 2023-06-27
US20220356235A1 (en) 2022-11-10
KR20200110688A (ko) 2020-09-24
IL276008A (en) 2020-08-31
CA3088507A1 (en) 2019-07-18
US12624094B2 (en) 2026-05-12
MX2020007555A (es) 2021-01-15
JP7471224B2 (ja) 2024-04-19

Similar Documents

Publication Publication Date Title
US12624094B2 (en) Factor H potentiating antibodies and uses thereof
US20240336676A1 (en) Factor h potentiating antibodies and uses thereof
JP2021178857A (ja) H因子を強化する抗体及びその用途
WO2026068532A1 (en) Bispecific binding molecule

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant